Analyzing India

Sector in Focus: NIFTY Pharma ($CNXPHARMA): Looking at a trend reversal after multi-year downtrend

Milan Vaishnav

Milan Vaishnav


Nifty Pharmaceutical Index - NIFTYPHARMA  ($CNXPHARMA) marked its high at 14,020 on 6th of April 2015 and since then it has remained in a falling channel under a corrective downtrend which has lasted over 3 years.

After remaining in a corrective downtrend for over 3 years, it has shown signs of a trend reversal. The Relative Strength (RS) when compared against the broader Market Index $CNX500 (NIFTY500) shows distinct improvement as it rules above its 50-Week MA and it is seen rising. A rise in the RS-Line means the Pharma Index in performing better when compared against Broader Markets, i.e.$CNX500 (NIFTY500)

The Pharma Index has shown breakout from the falling channel and has attempted a breakout. It suffered a classical throwback after that and it is seen consolidating near the levels from where it broke out. The breakout coupled with a breakout / reversal of trend in RS is a positive sign and it acts as a confirmation of the present attempt to reverse the long-term downtrend.

In coming weeks, Pharma Index is likely to show immense resilience if the volatility that is presently seen the Markets continues to dominate. In event of improvement in broader Markets, Pharma pack is likely to show distinct relative out-performance. The Index has potential to test 12,000 mark over  medium term. This translates into upside potential of ~26% from present levels.

This reversal would fail if the Index drops below 8500.

Milan Vaishnav, CMT, MSTA
Consulting Technical Analyst,
www.EquityResearch.asia

Milan Vaishnav
About the author: , CMT, MSTA is a capital market professional with experience spanning close to two decades. His area of expertise includes consulting in Portfolio/Funds Management and Advisory Services. Milan is the founder of ChartWizard FZE (UAE) and Gemstone Equity Research & Advisory Services. As a Consulting Technical Research Analyst and with his experience in the Indian Capital Markets of over 15 years, he has been delivering premium India-focused Independent Technical Research to the Clients. He presently contributes on a daily basis to ET Markets and The Economic Times of India. He also authors one of the India's most accurate "Daily / Weekly Market Outlook" -- A Daily / Weekly Newsletter,  currently in its 18th year of publication. Learn More